A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

NCT03410875 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hairy Cell Leukemia
Leukemia
Leukemia, Hairy Cell

Interventions

DRUG: Vemurafenib
DRUG: Obinutuzumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]